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A Ab bs st tr ra ac ct t
The extent to which common variants contribute to common phenotypes and disease in humans
has important consequences for the future of medical genomics. Two reports have recently
clarified this issue for one of the most pressing public health concerns, obesity. These large and
comprehensive genome-wide association studies find that common variants within at least 11
genes are associated with obesity. Interestingly, most of these genes are highly expressed in the
central nervous system, further highlighting its role in the pathogenesis of obesity. However, the
individual and combined effects of these variants explain only a small fraction of the inherited
variability in obesity, suggesting that rare variants may contribute significantly to the genetic
predisposition for this condition.
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G Ge en ne et ti ic c   f fa ac ct to or rs s   i in n   h hu um ma an n   o ob be es si it ty y
Obesity has become a major public health concern, as it
increases mortality and the risk of morbidity from hyper-
tension, dyslipidemia, diabetes mellitus and cardiovascular
disease [1,2]. Body mass index (BMI; weight divided by the
square of the height) is the most commonly used clinical
measure of adiposity, and individuals with a BMI above
30 kg/m2 are classified as obese. The most recent National
Health and Nutrition Examination Survey shows that the
prevalence of obesity among US adult men and women was
33.3% and 35.3%, respectively [3].
Both environmental and genetic factors are involved in the
onset and progression of weight gain [4]. Excess caloric
intake and the tendency towards a more sedentary lifestyle
are certainly to blame for the increased prevalence of
obesity, but individuals exposed to the same environmental
pressures have different levels of vulnerability. Indeed,
genetic epidemiologic studies, such as twin studies [5] and
adoption studies [6], have implicated genetic factors in the
susceptibility to obesity. These studies have shown that
genetic factors account for 40-70% of the population
variation in BMI and that the heritability of obesity increases
with its severity [7]. Emphasis has therefore now shifted
from the question of whether human obesity has a genetic
component to how many and which genetic variants
underlie this susceptibility [8,9].
In theory, genetic susceptibility to obesity in humans could
result from the additive effects of common genetic variants
(minor allele frequency >5%), from different rare mutations
in a large set of genes, or from a combination of both [8,9].
Several genes in which rare mutations cause severe mono-
genic or syndromic forms of obesity have been described,
and these have furthered our knowledge of the molecular
pathways involved in food intake regulation and the control
of body weight [10]. The genes implicated in these rare
human monogenic forms of obesity encode proteins that
have a role in the central regulation of energy homeostasis,
in particular at the level of the hypothalamus.T Th he e   c co om mm mo on n   v va ar ri ia an nt t   p pi ie ec ce e   o of f   t th he e   o ob be es si it ty y   p pi ie e
Hundreds of studies in the past 15 years have suggested a
positive association of common variants in a large number of
candidate genes with obesity or obesity-related phenotypes.
As for several other common diseases, most of these studies
failed to be replicated, being limited by their insufficient
sample size and by stratification and multiple testing issues [9].
In 2008, reports of the first genome-wide association studies
(GWASs) for obesity revealed previously unreported associa-
tions with common variants near the fat mass and obesity-
associated gene FTO [11], a gene with a yet unknown function,
and near the melanocortin 4 receptor (MC4R) gene [12], in
which multiple rare variants had previously been shown to
cause, in aggregate, 2-4% of severe obesity (BMI ≥40 kg/m2)
cases in humans [13,14]. These findings were replicated across
several populations, but the common alleles at these two loci
had only a modest effect on BMI (0.2-0.4 kg/m2), suggesting
that additional common variants could account for a
significant fraction of the inherited BMI population variation.
By combining extremely large samples of GWASs, recent
reports now provide us with a more comprehensive view of
the extent to which common variants are associated with
obesity [15,16]. Investigators of the Genetic Investigation of
Anthropometric Traits (GIANT) consortium conducted a
meta-analysis of GWASs from a total of 32,387 subjects of
European ancestry in 15 cohorts for association with BMI
[16]. The strongest signals from 35 variants were used for
follow-up in 14 additional cohorts with over 59,000 subjects
of European ancestry. In parallel, a group at deCODE
Genetics performed a GWAS with single nucleotide poly-
morphisms (SNPs) typed in over 30,000 individuals of
mixed descent (predominantly Icelandic, but also Dutch,
European American, African American and Scandinavian) in
search of polymorphic variants that affect variation in two
common measures of obesity, weight and BMI [15]. The
strongest signals from 43 variants were then tested for
association in 5,586 Danish individuals and compared in
silico with the results of the GIANT consortium [15].
Both studies confirmed the association of BMI with variants
at the FTO and MC4R genes and identified six and nine novel
loci, respectively, at which variants were associated with BMI
and/or weight, four of which (NEGR1, TMEM18, SH2B1 and
KCTD15) were common to both studies (Table 1).
Many of the new loci, in particular those found by the
GIANT consortium, are located near genes that are highly
expressed in the central nervous system, several in the
hypothalamus, possibly emphasizing, as in rare monogenic
forms of obesity, the role of the hypothalamus in the
predisposition to obesity. Of course, this conclusion is
preliminary, as the actual causative variants, which remain
to be identified by fine mapping at each of these loci, may
affect other genes in these regions.
In both studies, the allelic odds ratio for being obese
(BMI >30 kg/m2) remained greatest with the FTO variant
(Table 1), with odds ratios of 1.03-1.25 [16] and 1.07-1.27
[15]. All of the variants identified are relatively common, and
their combined effect explains only a small percentage of the
variation in weight and BMI. The GIANT consortium
examined the combined impact of the associated variants on
BMI. They weighted the number of BMI-increasing alleles by
their relative effect size and calculated a genotype score for
each individual. They found that individuals that have 13 or
more BMI-increasing alleles (representing 1.2% of the
sample) are only 0.59 kg/m2 heavier than the average
individual in their study. In addition, when the GIANT
consortium removed the associated loci from the analysis,
they no longer identified an excess of p-values smaller than
what is expected by chance [16]. The authors rightly argue
that common variants with even smaller effects may not
have been detected and could still be found with even larger
sample sizes. However, as these effects will be small, the data
from both studies suggest that most of the heritability of BMI
captured by common variants has been accounted for.
T Th he e   f fu ut tu ur re e   o of f   o ob be es si it ty y   g ge en ne et ti ic cs s: :   a a   c co om mm mo on n   d di is se ea as se e   b bu ut t
m ma an ny y   r ra ar re e   v va ar ri ia an nt ts s? ?
What then is the basis for the largest portion of BMI herita-
bility? One possibility, not yet explored extensively for
obesity, is a role for copy number variations. Such variations
have recently been implicated in the genetic predisposition
to common neurological diseases such as autism and schizo-
phrenia [17,18]. The GIANT consortium looked at the contri-
bution of copy number polymorphisms on BMI and found
that the SNP that was most strongly associated with one of six
loci, around the gene NEGR1, was linked to a 45-kb deletion
polymorphism [16]. This suggests that this copy number
polymorphism could be a candidate causal variant, and
further copy number variant studies may be deemed fruitful.
Both the GIANT and deCODE studies also acknowledge that
their results lend credence to the hypothesis that rare or
unique alleles with strong or intermediate effects could
account for the majority of one individual’s predisposition to
obesity. Testing this hypothesis, and finding genes for which
this is the case, will require comparative sequencing to
search for an increase in the aggregate number of rare
variants at each locus in cases versus controls. The largest
pioneering study yet to test this hypothesis sequenced the
entire coding region of 58 candidate genes in 379 extremely
obese and 378 extremely lean adults [19]. The authors found
an increase in unique non-synonymous variations in
severely obese individuals, specifically in a subset of genes
expressed in the central nervous system and for which the
corresponding mouse phenotype was suggestive of a role in
obesity. Searching for such loci systematically at a genome-
wide level will require extremely large-scale sequencing, for
which the technology is currently being developed and which
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logical difficulties pertaining, for example, to the functional
study and classification of identified variants.
Ultimately, the success of these approaches will depend on
the number of genes in which variations can predispose to
obesity and the effect size of both the individual variants and
their combined effect at each locus. We should now have
learned not to be too optimistic and expect the possibility
that the heritability of obesity may be accounted for by rare
or unique variations at hundreds of different genes.
A Ab bb br re ev vi ia at ti io on ns s
BMI, body mass index; GIANT, Genetic Investigation of
Anthropometric Traits consortium; GWAS, genome-wide
association studies; SNP, single nucleotide polymorphism.
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